Corrigendum to “Post-operative urinary retention is impacted by neuromuscular block reversal agent choice: A retrospective cohort study in US hospital setting” [Journal of Clinical Anesthesia Volume 93 (2024) 111344] (S0952818023002945), (10.1016/j.jclinane.2023.111344)

The authors regret an error in author affiliation (a). The correct authors’ affiliation should be Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, United States The authors further regret an error in reference to Table 2 and Figure 2 on page 4 of the text. The correct reference to these should read as follows: As expected, after matching, the cohorts treated with sugammadex and neostigmine were more similar to each other (Table 2). After matching, POUR incidence remained two-fold higher among those reversed with neostigmine than sugammadex among both inpatients and outpatients: 5.0% (n = 1533) vs. 2.4% (n = 751) and 0.9% (n = 421) vs 0.4% (n = 171), respectively; both p < 0.0001 (Fig. 2). The authors further regret an error on page 4, in sample sizes reported in Table 2. The outpatient and inpatient sample sizes in the header were inadvertently switched (the remainder of Table 2 is correct). The correct number of patients for the matched cohorts should appear in the header as follows: Table 2 Patient characteristics by NMB reversal agent choice after matching^a. [Table presented.] The authors further regret unclear footnotes a and b in Table 3. Correct footnotes should read as follows: ^a The model additionally adjusted for diagnosis of congestive heart failure, obesity, perioperative opioid use, NMB (vecuronium, rocuronium), scopolamine use, and site sugammadex reversal rate in prior year among matched cohorts (not shown). ^b The model additionally adjusted for presence of ≥1 comorbidities, diagnosis of sleep apnea, obesity, perioperative opioid use, NMB (vecuronium, rocuronium), scopolamine use, and site sugammadex reversal rate in prior year among matched cohorts (not shown). Instead of: ^aThe model adjusted for diagnosis of congestive heart failure, obesity, perioperative opioid use, NMB reversal agent (vecuronium, rocuronium), scopolamine use, and site sugammadex reversal rate in prior year among matched cohorts; only statistically significant findings are shown above. ^bThe model adjusted for presence of ≥1 comorbidities, diagnosis of sleep apnea, obesity, perioperative opioid use, NMB reversal agent (vecuronium, rocuronium), scopolamine use, and site sugammadex reversal rate in prior year among matched cohorts; only statistically significant findings are shown above. [Table presented.][Formula presented] The authors would like to apologise for any inconvenience caused.